We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New Radioactive Agents for Colon Cancer Work Inside Cells

By Biotechdaily staff writers
Posted on 23 Oct 2007
Researchers have developed a potentially novel way to fight colorectal cancer utilizing tiny molecules to deliver potent barrages of radiation inside cancer cells, unlike existing treatments that bind to the surface of cells and attack from the outside and cause unwanted side effects. More...


In laboratory studies with normal and cancer cells, the new radiation delivery system proved able to precisely target colon cancer cells, and what remains is likely to be easily filtered out by the kidneys because the delivery system's molecules are so small.

As reported in the October 3, 2007, issue of the journal PLoS One, Johns Hopkins University (Baltimore, MD, USA) colorectal cancer specialists John Abraham, Ph.D., and Stephen Meltzer, M.D., working with the theory that small molecules typically make better treatment vehicles--designed small pieces of protein, only 10 amino acids long as the foundation for their drugs. By contrast, antibodies used to deliver radiation or chemicals can be over 1,000 amino acids long.

The team attached radioactive phosphorous, P32, as a test of how well their peptides worked and "to our surprise, our first tests showed that cells were ingesting these molecules, thus transferring the radiation inside and killing them by breaking up their DNA and proteins,” Dr. Abraham said.

While cautioning that the new radiation delivery system is still far from ready for use in humans, Dr. Abraham noted that P32 gives off high energy that can penetrate through 5-mm of human tissue, making it a good candidate for fighting colon cancer since colon cancer cells can frequently form large, thick tumors into which drugs may not penetrate very well. Moreover, P32-labeled peptides may serve another valuable use: to find small metastases or recurrences of colon tumors while they are still small enough to treat. Images of the body can be taken of the labeled peptides as they bind, revealing where stray tumor cells may be nesting.

The investigators then designed and evaluated a variety of P32-peptides on 18 normal and cancerous human cell samples. The most potent peptide, MA5, was shown to be able to bind to adenocarcinoma cells, which make up 95% of all colon cancers, 150 times more strongly than other cell types and be delivered inside cells within two hours.


Related Links:
Johns Hopkins University

Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.